Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
Status:
Not yet recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
This study designed to assess the efficacy of osimertinib (80 mg, orally, once daily) to
suppress the progression of remaining GGN(s) in other lobes following surgical resection for
actionable EGFR mutation-positive stage I lung adenocarcinoma.